Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2015

01-08-2015 | PHASE I STUDIES

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose

Authors: Karthik Venkatakrishnan, Tae Min Kim, Chia-Chi Lin, Lim Soon Thye, Wee Joo Chng, Brigette Ma, Ming Huang Chen, Xiaofei Zhou, Hua Liu, Virginia Kelly, Won Seog Kim

Published in: Investigational New Drugs | Issue 4/2015

Login to get access

Summary

Purpose This phase 1 study assessed the pharmacokinetics (PK), maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), safety, and preliminary efficacy of the investigational Aurora A kinase inhibitor, alisertib, in East Asian patients with advanced solid tumors or lymphomas. Patients and Methods Patients received alisertib twice-daily (BID) for 7 days in 21-day cycles. Doses were escalated (3 + 3) from 30 mg BID based on cycle 1 dose-limiting toxicities (DLTs) until the MTD, followed by expansion for PK/safety characterization. Results Thirty-six patients (61 % Chinese, 36 % Korean, 3 % Malay) received alisertib (30 mg BID, n = 30; 40 mg BID, n = 6; median, 2.5 cycles). Alisertib exposures increased approximately dose proportionally, and mean half-life was 16 h. Geometric mean apparent oral clearance (2.65 L/h) was 40 % lower than previous estimates in Western patients, resulting in approximately 70 % higher mean dose-normalized, steady-state exposures (735 nM*h/mg) in East Asian patients. Two patients experienced DLTs at 40 mg BID (grade 3 stomatitis; grade 4 neutropenia); the MTD/RP2D was 30 mg BID. Common toxicities (grade ≥3 at RP2D) were neutropenia (50 %), diarrhea (13 %), and stomatitis (10 %). One patient with extranodal T-/NK-cell lymphoma (nasal type) achieved a partial response and 18 (51 %) had stable disease. Conclusion The MTD/RP2D of alisertib in East Asian patients (30 mg BID) was lower than in Western patients (50 mg BID), consistent with higher systemic exposures in the East Asian population. Alisertib was generally well tolerated and showed signs of antitumor activity in East Asian cancer patients.
Appendix
Available only for authorised users
Literature
1.
Carvajal RD, Tse A, Schwartz GK (2006) Aurora kinases: new targets for cancer therapy. Clin Cancer Res 12(23):6869–6875PubMedCrossRef
2.
Lu LY, Wood JL, Ye L, Minter-Dykhouse K, Saunders TL, Yu X et al (2008) Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem 283(46):31785–31790PubMedCentralPubMedCrossRef
3.
Barr AR, Gergely F (2007) Aurora-A: the maker and breaker of spindle poles. J Cell Sci 120(Pt 17):2987–2996PubMedCrossRef
4.
Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5(1):1–10PubMedCrossRef
5.
Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E et al (2003) Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278(51):51786–51795PubMedCrossRef
6.
Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M et al (2010) A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115(25):5202–5213PubMedCentralPubMedCrossRef
7.
Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B et al (2010) MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 8(3):373–384PubMedCrossRef
8.
Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A et al (2008) Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 112(8):1688–1698PubMedCentralPubMedCrossRef
9.
Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T et al (2009) Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 114(13):2699–2708PubMedCrossRef
10.
Evans R, Naber C, Steffler T, Checkland T, Keats J, Maxwell C et al (2008) Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 49(3):559–569PubMedCrossRef
11.
Hoque A, Carter J, Xia W, Hung MC, Sahin AA, Sen S et al (2003) Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev 12(12):1518–1522PubMed
12.
Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL (2009) Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 31(5):625–634PubMedCentralPubMedCrossRef
13.
Tomita M, Toyota M, Ishikawa C, Nakazato T, Okudaira T, Matsuda T et al (2009) Overexpression of Aurora A by loss of CHFR gene expression increases the growth and survival of HTLV-1-infected T cells through enhanced NF-kappaB activity. Int J Cancer 124(11):2607–2615PubMedCrossRef
14.
Yang SB, Zhou XB, Zhu HX, Quan LP, Bai JF, He J et al (2007) Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. Oncol Rep 17(5):1083–1088PubMed
15.
Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH et al (2009) Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop 2(1):2–8PubMedCentralPubMedCrossRef
16.
Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ et al (2008) Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 7(9):1388–1397PubMedCrossRef
17.
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B et al (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17(11):3052–3065PubMedCentralPubMedCrossRef
18.
19.
Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T et al (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25(54):7148–7158PubMedCrossRef
20.
Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM et al (2011) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17(24):7614–7624PubMedCrossRef
21.
Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL et al (2011) Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 68(5):1291–1304PubMedCentralPubMedCrossRef
22.
Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST et al (2011) The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 15(10):2057–2070PubMedCentralPubMedCrossRef
23.
Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S et al (2012) Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer 131(11):2693–2703PubMedCentralPubMedCrossRef
24.
Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H et al (2010) Initial testing of the aurora kinase A inhibitor MLN8237 by the pediatric preclinical testing program (PPTP). Pediatr Blood Cancer 55(1):26–34PubMedCentralPubMed
25.
Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO et al (2013) Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 37(4):434–439PubMedCrossRef
26.
Sehdev V, Katsha A, Ecsedy J, Zaika A, Belkhiri A, El-Rifai W (2013) The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer 119(4):904–914PubMedCentralPubMedCrossRef
27.
Tomita M, Mori N (2010) Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci 101(5):1204–1211PubMedCrossRef
28.
Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K et al (2012) Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18(17):4764–4774PubMedCrossRef
29.
Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K et al (2012) Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18(17):4775–4784PubMedCrossRef
30.
Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X et al (2014) Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Investig New Drugs 32(6):1181–1187CrossRef
31.
Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT et al (2014) Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Investig New Drugs 32(3):489–499CrossRef
32.
Beltran H, Rubin MA, Mosquera JM, Christos PJ, Calukovic O, Karpenko I et al (2013) A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer. (Abstract). J Clin Oncol (ASCO 2013 Annual Meeting) 31(Suppl): Abstract TPS5096.
33.
Dickson MA, Mahoney MR, Tap WD, D’Angelo SP, Keohan ML, Van Tine BA et al (2014) Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma (Abstract). J Clin Oncol (ASCO 2014 Annual Meeting) 32(5s):Abstract 10527.
34.
Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB et al (2014) Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 32(1):44–50PubMedCentralPubMedCrossRef
35.
Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I et al (2012) Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 127(1):63–69PubMedCrossRef
36.
Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O et al (2015) Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol 16(4):395–405PubMedCrossRef
37.
Venkatakrishnan K, Zhou X, Ecsedy J, Mould DR, Liu H, Danaee H et al (2014) Dose selection for the investigational anticancer agent alisertib (MLN8237): pharmacokinetics, pharmacodynamics, and exposure-safety relationships. J Clin Pharmacol. doi:10.​1002/​jcph.​410
38.
39.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205PubMedCrossRef
40.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRef
41.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586PubMedCrossRef
42.
Asano K, Tanaka A, Sato T, Uyama Y (2013) Regulatory challenges in the review of data from global clinical trials: the PMDA perspective. Clin Pharmacol Ther 94(2):195–198PubMedCrossRef
43.
Zhou X, Pusalkar S, Chowdhury S, Searle S, Li Y, Mertz J et al (2013) Mass balance, routes of excretion and pharmacokinetics of investigational oral [14C] alisertib (MLN8237) in patients with advanced solid tumors or lymphoma (Abstract). AACR-NCI-EORTC 2013 Symposium on Molecular Targets and Cancer Therapeutics Annual Meeting: Abstract B216.
44.
Barter ZE, Tucker GT, Rowland-Yeo K (2013) Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet 52(12):1085–1100PubMedCrossRef
45.
Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol 13(8):790–801PubMedCrossRef
46.
Ichimaru K, Toyoshima S, Uyama Y (2010) Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Clin Pharmacol Ther 87(3):362–366PubMedCrossRef
Metadata
Title
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
Authors
Karthik Venkatakrishnan
Tae Min Kim
Chia-Chi Lin
Lim Soon Thye
Wee Joo Chng
Brigette Ma
Ming Huang Chen
Xiaofei Zhou
Hua Liu
Virginia Kelly
Won Seog Kim
Publication date
01-08-2015
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2015
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-015-0258-y

Other articles of this Issue 4/2015

Investigational New Drugs 4/2015 Go to the issue

PHASE II STUDIES

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

PHASE I STUDIES

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

PRECLINICAL STUDIES

In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis

PHASE I STUDIES

Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib

PHASE II STUDIES

A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study

PHASE I STUDIES

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits